Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

HRTS

Tema Cardiovascular and Metabolic ETF (HRTS)

Rating:67Neutral
Price Target:$40.00â–²(1.93% Upside)

HRTS, the Tema Cardiovascular and Metabolic ETF, earns a solid overall rating driven by strong core holdings like Eli Lilly, Merck, Johnson & Johnson, and Gilead, which combine robust financial performance, attractive growth prospects, and supportive earnings outlooks. The fund’s score is held back somewhat by weaker names such as BridgeBio Pharma, where negative profitability and high leverage add risk, and by broader concerns like high valuations and leverage among several top positions. The main risk factor is its concentration in a specialized healthcare niche, where company-specific challenges or sector-wide setbacks could have an outsized impact on the ETF.

Positive Factors
Strong Overall PerformanceThe fund has shown steady gains so far this year and in recent months, indicating positive momentum.
Leading Health Care HoldingsSeveral major positions in well-known health care companies have delivered strong results, supporting the ETF’s performance.
Focused Exposure to Cardiovascular and Metabolic HealthThe ETF’s heavy tilt toward the health care sector gives targeted exposure to a specialized area that many investors may find attractive.
Negative Factors
High Sector ConcentrationNearly all assets are in health care, so the fund is heavily exposed to risks specific to that industry.
Single-Country DominanceThe portfolio is mostly invested in U.S. companies, offering limited diversification across global markets.
Relatively High Expense RatioThe fund’s fee is on the higher side for an ETF, which can reduce the net return that investors receive over time.

HRTS vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%SPY+14.55%HRTS+14.65%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
57.71M
Region
Global
Expense Ratio
0.75%
Beta
0.60
Issuer
Tema
Inception Date
Nov 21, 2023
Dividend Yield
1.21%
Asset Class
Equity
Index Tracked
No Underlying Index

HRTS Summary

The Tema Cardiovascular and Metabolic ETF (HRTS) is a health care fund focused on companies working on heart disease, diabetes, and other metabolic conditions, mainly in the U.S. It does not track a traditional index, but instead follows a theme of pharma, biotech, and life sciences firms driving new treatments and medical technologies. Well-known holdings include Eli Lilly and Johnson & Johnson. Someone might invest in HRTS for growth potential from medical innovation and to get targeted exposure to leading health care companies. A key risk is that it is heavily concentrated in one sector, so its value can rise or fall sharply with health care stocks.

How much will it cost me?

This ETF has an expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed and focused on a specialized niche in cardiovascular and metabolic health, which typically costs more to run than broad, passive index funds.

What would affect this ETF?

HRTS could benefit from growing global demand for treatments for heart disease and diabetes, successful new drug approvals from major holdings like Eli Lilly, Merck, and Johnson & Johnson, and continued innovation in biotech and life sciences. On the negative side, it is heavily concentrated in health care, so tighter drug pricing rules, regulatory setbacks, or changes in insurance and reimbursement policies around the world could hurt the fund’s companies and weigh on future returns.

HRTS Top 10 Holdings

HRTS is leaning heavily on health care powerhouses, with Eli Lilly acting as the fund’s engine thanks to its rising momentum in diabetes and obesity treatments. Thermo Fisher, Roche, and Johnson & Johnson add steady, broadly rising support, giving the portfolio a solid backbone of established global names. On the flip side, Revolution Medicines and Kodiak Sciences bring high‑octane biotech potential but also inject volatility, sometimes dragging on short‑term results. Overall, this is a globally focused, cardiometabolic‑themed fund, concentrated in health care and tilted toward a mix of blue-chip stability and speculative biotech upside.

HRTS top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
LLYLLYEli Lilly & Co12.63%$7.29M$1.36T41.12%72Outperform
TMOTMOThermo Fisher5.31%$3.06M$259.44B20.70%72Outperform
RHHBYRHHBYRoche Holding4.32%$2.49M$384.64B32.47%74Outperform
MRKMRKMerck & Company4.19%$2.42M$364.26B59.00%80Outperform
KODKODKodiak Sciences4.05%$2.34M$7.27B489.24%35Underperform
BBIOBBIOBridgeBio Pharma3.69%$2.13M$15.25B20.35%59Neutral
GILDGILDGilead Sciences3.39%$1.96M$208.48B34.25%78Outperform
RVMDRVMDRevolution Medicines3.26%$1.88M$37.27B167.61%52Neutral
DHRDHRDanaher3.10%$1.79M$163.94B5.34%75Outperform
JNJJNJJohnson & Johnson2.87%$1.66M$687.89B46.35%78Outperform

HRTS Technical Analysis

Technical Analysis SentimentPositive
Last Price39.24

Price Trends

50DMA37.15Positive
100DMA37.12Positive
200DMA35.70Positive

Market Momentum

MACD0.65Negative
RSI60.54Neutral
STOCH61.23Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HRTS, the sentiment is Positive. The current price of 39.24 is above the 20-day moving average (MA) of 38.42, above the 50-day MA of 37.15, and above the 200-day MA of 35.70, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 60.54 is Neutral, neither overbought nor oversold. The STOCH value of 61.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HRTS.

HRTS Peer Comparison

Comparison Results

HRTS against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
HRTSHRTS$39.24$40.00(1.93% Upside)$57.71M0.75%67Neutral
OZEMOZEM$31.42$48.37(53.98% Upside)$57.30M0.59%57Neutral
MEDIMEDI$36.34$46.47(27.90% Upside)$44.15M0.80%62Neutral
PSILPSIL$19.23$58.19(202.59% Upside)$41.90M1.00%44Neutral
TMEDTMED$34.80$54.70(57.19% Upside)$41.60M0.44%60Neutral
GDOCGDOC$39.33$44.91(14.20% Upside)$20.55M0.75%71Outperform

Performance Comparison

0%20%40%60%HRTSOZEMMEDIPSILTMEDGDOCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HRTS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HRTSTema Cardiovascular and Metabolic ETF39.245.3115.65%
OZEMRoundhill GLP-1 & Weight Loss ETF31.41-0.42-1.31%
MEDIHarbor Health Care ETF36.344.9115.61%
PSILAdvisorShares Psychedelics ETF19.232.7716.80%
TMEDT. Rowe Price Health Care ETF34.805.8019.98%
GDOCGoldman Sachs Future Health Care Equity ETF39.333.6310.17%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.